Research Area:

Small Cell Lung Cancer

AMG 757

Amgen Study ID Number: 20160323 • NCT: 03319940


A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Patients With Small Cell Lung Cancer

Primary Endpoints:

- Dose-limiting toxicities (DLTs)
- Treatment-emergent adverse events (TEAEs)
- Treatment-related adverse events (TRAEs)

Key Secondary Endpoints:

- Overall response rate (ORR) per RECIST v1.1
- Duration of response (DOR)
- Progression-free survival (PFS) and Overall survival (OS)
- Pharmacokinetics



MTD, maximum tolerated dose; RECIST, response evaluation criteria in solid tumors; RP2D, recommended phase 2 dose; SCLC, small cell lung cancer.

AMGEN

Oncology

Product has not been authorised by regulatory agencies for marketing and is only authorised for investigational use in this trial.

AMG 757

Key Summary Points:

This is an open-label, ascending, multiple dose, phase 1 study evaluating AMG 757 as monotherapy and in combination with anti-PD1 therapy. AMG 757 will be administered as a short term intravenous (IV) infusion every 2 weeks (with or without step dosing) in subjects with SCLC.

The dose exploration phase of the study will estimate the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of AMG 757 either as monotherapy or in combination with anti-PD1 therapy.

Additional Information:

- www.clinicaltrials.gov Identifier-NCT03319940
- www.amgentrials.com Protocol Number-20160323

ECOG, Eastern Cooperative Oncology Group ED, extensive disease PD1, programmed cell death protein 1 RR, relapsed or refractory SCLC, small cell lung cancer TRAE, treatment-related adverse event

Key Inclusion Criteria:

- Age \geq 18 years old
- Histologically or cytologically confirmed SCLC
 - Part A and Part C: RR SCLC who progressed or recurred following platinum-based chemotherapy
 - Part B: ED SCLC with ongoing clinical benefit following no more than 6 cycles of first-line platinum-based chemotherapy with last dose of chemotherapy ≥ 28 days prior to the study day 1
- ECOG performance status of 0-2

Key Exclusion Criteria:

- History of other malignancy within past 2 years prior to first dose of AMG 757 with exceptions
- Untreated or symptomatic brain metastases and leptomeningeal disease
- Prior anti-cancer therapy: at least 28 days must have elapsed between any prior anti-cancer therapy and first dose of AMG 757 Exceptions:
 - At least 14 days since chemotherapy and all TRAE has resolved to ≤ Grade 1
 - Completion of prior palliative radiotherapy at least 7 days prior to first AMG 757 dose
- Patients who experienced severe, life-threatening or recurrent (Grade ≥ 2) immune-mediated adverse events, or infusion-related reactions from immuneoncology therapy
- Evidence of interstitial lung disease or active non-infectious pneumonitis
- Diagnosis of immunodeficiency or receiving systemic steroid therapy or immunosuppressive therapy within 7 days of first AMG 757 dose
- Part C: History of solid organ transplant or active autoimmune disease requiring systemic treatment within past 2 years

Amgen (Europe) GmbH, 6343 Risch-Rotkreuz, Switzerland Date of Preparation: August 2020 ©2020 Amgen Inc. All rights reserved. SC-EU-AMG 757-00002



Oncology